Humedics Invests in G2G Bio... Accelerating Development of Long-Lasting Efficacy Injectable Drugs

On the 19th, at the Humedix headquarters in Pangyo, Seongnam-si, Gyeonggi Province, Kim Jin-hwan, CEO of Humedix, and Lee Hee-yong, CEO of G2G Bio (from left in the photo), signed a strategic investment agreement for collaboration in the sustained-release injectable drug business and are taking a commemorative photo. (Photo by Humedix)

[Asia Economy Reporter Chunhee Lee] Humedix is strengthening its collaboration with G2G Bio, with which it is jointly developing a long-acting sustained-release injectable drug.

On the 19th, Humedix announced on the 20th that it signed a strategic equity investment contract worth 2 billion KRW to strengthen business cooperation, including the sustained-release injectable drug jointly developed with G2G Bio, at its headquarters in Pangyo, Seongnam-si, Gyeonggi Province.

This contract is an advancement of the "business agreement for joint development of long-acting sustained-release injectable drugs" signed last October. Through technical review and business exchanges between the two companies, it was concluded that G2G Bio's sustained-release microparticle manufacturing technology, InnoLAMP, has great technological capability, potential, and market competitiveness, leading to this decision.

Based on the strengthened partnership, the two companies plan to accelerate the development and commercialization of long-acting sustained-release injectable drugs. G2G Bio will focus on commercializing pipelines targeting Alzheimer's treatment 'GB-5001', diabetes, and osteoarthritis using the investment funds, and later seek commercialization and overseas expansion through Humedix, which has extensive experience and technology in manufacturing finished injectable products.

Long-acting sustained-release injectable drugs, also called sustained-release injectables, are a new form of medicine that replaces drugs requiring daily oral or injectable administration with injections given once every 1 to 3 months. The method involves injecting the drug subcutaneously or intramuscularly to release the drug into the bloodstream over an extended period or expanding the molecular structure to prolong the drug's efficacy duration. This is emerging as a new alternative to reduce the burden of medication for patients with intractable diseases who need daily medication or injections.

Jinhwan Kim, CEO of Humedix, said, "We are actively promoting technology exchange and strategic business cooperation with promising bio-technology companies like G2G Bio that possess proprietary technology," adding, "Through this investment, we hope to secure a leading position in the future-competitive field of sustained-release injectable drugs and build a stronger partnership."

Heeyong Lee, CEO of G2G Bio, also said, "G2G Bio pursues a development strategy to maximize the efficiency of drug application in the human body," and added, "Since G2G Bio's technology uses drug substances whose clinical efficacy and market competitiveness have already been confirmed, it can improve patient medication adherence, convenience, and bioavailability, enabling rapid penetration into the unmet medical needs market."